Compared to another common class of kidney medications, called DPP4is, GLP1-RA medications did better in helping slow the progression of kidney disease, keeping kidney disease patients out of the ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Their relationship is still going strong. Patrick Mahomes and Travis Kelce said that it was 'a great honor' for the president ...

Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury's out on whether ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.OtgQHJex.js ...

This is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on over ...

WVU medicine is conducting a trial to combat weight gain after patients stop taking GLP-1 drugs such as Ozempic. Officials ...